Razvan Claudiu Cerban

Dr. Razvan Claudiu Cerban


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2023 in Life
Verified
Journal Article
Open access
PDF file
RGRaluca Roxana Grigorescu
Raluca Roxana Grigorescu
IHIoana Alexandra Husar-Sburlan
Ioana Alexandra Husar-Sburlan
GRGeorgiana Florentina Rosulescu
Georgiana Florentina Rosulescu
ABAnca Bobirca
Anca Bobirca
RCRazvan Claudiu Cerban
Razvan Claudiu Cerban
FMFlorescu Madalina
Florescu Madalina
In recent years, we have faced an increasing incidence of inflammatory bowel disease (IBD), especially among young people, affecting them during their reproductive years. The paucity of data and reduced knowledge regarding the evolution of the disease during pregnancy and the adverse effects of the therapy on the mother and infant increase voluntary childlessness in this group of patients. Depending on the type of IBD, severity and surgical or medical management, this can negatively affect the pregnancy. C-sections and the risk of low-birth-weight babies are higher in women with IBD, independent of active/inactive disease, while preterm birth, stillbirth and miscarriage are associated with disease activity. In the last period, medicinal therapy has evolved, and new molecules have been developed for better control of the lesions, but the effect on pregnancy and breastfeeding is still controversial. We conducted this review by studying the literature and recent research in order to have a better image of the practical management of IBD during pregnancy.

21 September 2021 in Journal of Gastrointestinal and Liver Diseases
Verified
Journal Article
Open access
PDF file
FMFlorescu Madalina
Florescu Madalina
ACAdrian Costache
Adrian Costache
SISperanta Iacob
Speranta Iacob
CPCorina Pietrareanu
Corina Pietrareanu
CECarmen Ester
Carmen Ester
LGLiliana Gheorghe
Liliana Gheorghe
Background and Aims: The evidence regarding the use of anticoagulant (AC) agents in portal vein thrombosis (PVT) is increasing and, most patients undergo chronic treatment with low molecular weight heparin (LMWH) or vitamin K antagonists (VKA). Nevertheless, there are no clear data about who should receive antithrombotic therapy, when to initiate it, how long and what dose should be used for this set of patients. The aim of the study was to assess the outcome of patients with cirrhosis and portal vein thrombosis who received AC therapy, in terms of thrombus regression, bleeding events and survival rates. Methods: This observational and retrospective study included 107 cirrhotic patients diagnosed with PVT in a single tertiary center between 2010-2019. 54 received low molecular weight heparin or vitamin K antagonist (AC treatment group) and 53 were untreated. All patients were periodically follow-up to assess the evolution of PVT (regression, progression, stable thrombus) and potential occurrence of bleeding events. Results: The regression of portal vein thrombosis was significantly higher in the AC treatment group (OR=2.430; 95% CI=1.11-6.167; p=0.026), more than 50% of on-treatment patients experiencing regression of the thrombus. However, bleeding events were significantly more frequent in the AC treatment group (18.5% vs. 7.5%) and the risk of bleeding was associated with thrombocytes less than 50x103/mm3 (OR=8.266; 95%CI: 2.310-39.211; p=0.002). Survival was better in the AC treatment group (68.4% vs 48.7% at 5 years and 92.7% vs 77.8% at 1 year, p=0.038) and was lower in patients that experienced bleeding events (37.22% survival at 5 years, mean time survival 44 months, p=0.008). Conclusions: In our cohort of cirrhotic patients with PVT more than 50% of patients receiving AC therapy presented regression of the thrombus; most of them obtained partial recanalization. The bleeding complication rate was higher than expected, reaching 18%. The overall mortality was lower in the treated group.

29 June 2024 in Journal of Gastrointestinal and Liver Diseases
Verified
Journal Article
Open access
PDF file
Rares CraciunRares Craciun
Rares Craciun
HSHoria Stefanescu
Horia Stefanescu
Ioan SporeaIoan Sporea
Ioan Sporea
DSDaniela Larisa D Sandulescu
Daniela Larisa D Sandulescu
LGLiliana Gheorghe
Liliana Gheorghe
MGMircea Grigorescu
Mircea Grigorescu
Background and Aims: Hepatocellular carcinoma (HCC) is a significant public health issue, with an increasing incidence and prevalence and a high incidence-to-mortality ratio. The prognosis of HCC depends on two competing factors, tumor burden and underlying liver disease severity, encompassed in the Barcelona Clinic Liver Cancer (BCLC) classification. To assess HCC staging and the way staging affects eligibility for treatment at the time of the first diagnosis in Romania in the setting of opportunistic diagnosis, in the absence of a national HCC screening policy. Methods: Data regarding HCC staging, underlying liver disease, and eligibility for treatment at the time of diagnosis was analyzed using a prospectively maintained multicentric database, which included patients from the five largest tertiary care hepatology units in the country between June 2016 and February 2020. Results: A consecutive series of 477 patients was included. The distribution within BCLC classes was as follows: very early (0) 7.1%, early (A) 34.3%, intermediate (B) 19.4%, advanced (C) 14.2%, terminal (D) 24.7%. At the time of the diagnosis, 198 (41.5%) were eligible for a curative intent treatment, while 359 (75.2%) were eligible for a disease-modifying therapy. 228 patients (47.8%) had decompensated liver disease at the time of diagnosis, the most common decompensating event being ascites (78.1%). Conclusions: A large proportion of HCC cases are diagnosed at the time of a decompensating event, severely restricting the therapeutic potential. Proactive diagnostic strategies should be implemented to improve the rate of actionable diagnosis.

1 January 2019 in Surgery, Gastroenterology and Oncology
Verified
Journal Article
Open access
PDF file
RCRazvan Claudiu Cerban
Razvan Claudiu Cerban
CECarmen Ester
Carmen Ester
SISperanţa Iacob
Speranţa Iacob
MGMihaela Ghioca
Mihaela Ghioca
LPLiliana Paslaru
Liliana Paslaru
LGLiliana Gheorghe
Liliana Gheorghe

25 April 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
RCRazvan Claudiu Cerban
Razvan Claudiu Cerban
SISperanta Iacob
Speranta Iacob
CECarmen Ester
Carmen Ester
MGMihaela Corina Ghioca
Mihaela Corina Ghioca
MCMirela Chitul
Mirela Chitul
LGLiliana Gheorghe
Liliana Gheorghe
Hepatocellular carcinoma (HCC), a common consequence of chronic liver disease, ranks among the most prevalent cancers globally and contributes significantly to cancer-related mortality. Liver fibrosis is intimately associated with hepatic function and the likelihood of future HCC occurrence. Despite the fact that liver biopsy continues to be the gold standard for diagnosing fibrosis, its utility is hindered by cost and invasiveness, along with patient unease, procedural rejection, and potential adverse effects. Liver elastography has become a leading noninvasive means of assessing tissue stiffness with considerable diagnostic precision. Malignant tumors generally exhibit higher cellularity in comparison to benign ones, resulting in increased stiffness. Elastography techniques capitalize on alterations in tissue elasticity stemming from specific pathological or physiological processes. Technological innovations, such as advanced ultrasound imaging and artificial intelligence (AI)-integrated systems, are paving the way for enhanced diagnostic accuracy and risk prediction. Recent research underscores the potential of elastography in managing HCC patients, presenting novel clinical applications, including prediction of HCC development, differentiation between malignant and benign liver lesions, evaluating treatment response, and forecasting recurrence post-treatment, though certain findings remain contentious. Therefore, this review aims to sum up the latest advancements in liver elastography for HCC patients, outlining its applications while addressing existing limitations and avenues for future progress.

21 October 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
SISperanta Iacob
Speranta Iacob
MCMirela Chitul
Mirela Chitul
VBVlad Brasoveanu
Vlad Brasoveanu
RCRazvan Claudiu Cerban
Razvan Claudiu Cerban
ICIleana Constantinescu
Ileana Constantinescu
LGLiliana Gheorghe
Liliana Gheorghe
Background/Objectives: Chronic hepatitis B virus (HBV)/hepatitis D virus (HDV) coinfection is a major cause of cirrhosis and hepatocellular carcinoma (HCC) and remains a disproportionately frequent indication for liver transplantation (LT) in Romania, one of the highest-HDV-prevalence countries in Europe, yet patient-level outcome data from this high-burden Eastern European setting are lacking. We report the ten-year outcomes of LT for HBV/HDV-related cirrhosis in a large single-centre Romanian cohort. Methods: We retrospectively analysed 236 adults transplanted for HBV/HDV-related cirrhosis at a single tertiary centre. Survival was estimated by the Kaplan-Meier method and predictors were assessed by Cox regression. HBV, HDV and HCC recurrence, and anti-HBs kinetics under combined hepatitis B immunoglobulin (HBIG)/nucleos(t)ide-analogue prophylaxis, were analysed. Results: Over a median follow-up of 8.1 years (maximum 14.4), overall survival was 89.8%, 82.8% and 79.5% at 1, 5 and 10 years; among 90-day survivors, conditional survival reached 86.9% at 10 years. Under an “on-demand” low-dose HBIG protocol combined with nucleos(t)ide analogues, HBV recurrence (HBsAg reappearance) occurred in 4.7% and HDV recurrence in 1.7% of patients, without graft dysfunction or death attributable to viral recurrence; anti-HBs titres stabilised at 120–140 IU/L beyond the first year, with approximately 60% of patients maintaining levels above 100 IU/L long-term. HBsAg reappearance occurred exclusively in HCC recipients (11/87 vs. 0/149, p < 0.001) and clustered in patients with tumour recurrence (9/17 vs. 2/70, p < 0.001), preceding the radiological diagnosis of recurrence in six of the nine patients concerned. Mortality was concentrated in the perioperative period (90-day mortality 8.5%), driven mainly by sepsis and surgical complications, and recurrent HCC was the most common recorded cause of late death. Neither the severity of liver disease at listing (MELD, ALBI) nor any viral variable was associated with survival; HCC as indication was associated with survival in univariable analysis and beyond-Milan tumour burden independently (HR 2.74, 95% CI 1.36–5.54). Conclusions: LT for HBV/HDV-related cirrhosis achieves excellent long-term survival and very low viral recurrence under combined prophylaxis, even in this HDV-hyperendemic setting; beyond the perioperative period, viral factors were not associated with survival, whereas beyond-Milan tumour burden was associated with worse survival in one of the sensitivity analyses. In this HBV/HDV cohort, HBsAg reappearance after transplantation for HCC was associated with tumour recurrence and may be regarded as a warning sign prompting oncological reassessment; whether it represents a true early marker requires prospective validation.